Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that in a recently released independent study, Plandai Biotechnology Inc.'s flagship product demonstrated a twelve-times greater efficacy in killing the malaria parasite.
This industry-leading performance may serve as a major boon to treating a disease which potentially impacts hundreds of millions of people and kills 600,000 in the African continent alone. Plandai is a developer of highly bioavailable, phytonutrient rich extracts (like EGCG), which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.
Interestingly, the Company elected to use the complete Phytofare™ complex and not just the isolated EGCG (Epigallocatechin Gallate) catechin used in earlier studies. Clearly, these results show the effectiveness of using a commercial botanical extract, rather than purified extract of EGCG catechin, as an anti-malarial.
A key takeaway of these results is the notion that confirms Plandai's offerings provide the greatest efficacy of green tea catechins in the industry and this substantial antioxidant activity can potentially be formulated to treat and protect many other immune system conditions in addition to malaria.
To that end, management plans to complete a commercial delivery system by encapsulating Phytofare™ Catechin Complex into a proprietary nano-delivery system that is expected to deliver improved absorption and protection against gut metabolization, allowing super antioxidants to remain protected and intact until they reach the bloodstream.
In addition, further independent scientific investigations of Phytofare™ Catechin Complex in powder and nano-encapsulated forms will be undertaken both in vitro and in mouse models to validate the extract for oral consumption as an antimalarial drug target and in topical formulations for anti-aging and other applications as well.
With substantial absorption advantages, the innovative delivery system under development and the potential adaptability of its core offerings for the prevention and treatment of a multitude of conditions, Plandai is poised to serve as a supplier of the next generation of improved nutraceutical ingredients.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.